VALN
$10.32-0.18 (-1.67%)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Recent News
Valneva Q4 Earnings Call Highlights
Valneva (NASDAQ:VALN) executives highlighted steady full-year 2025 revenue, tighter cash discipline, and multiple clinical and commercial catalysts during the company’s results and business update call. Management reiterated that upcoming pivotal phase 3 data for its Lyme disease vaccine candidate,
Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Valneva SE (INRLF) reports robust revenue growth and strategic progress in vaccine development, despite facing operational losses and increased R&D expenses.
Sector Update: Health Care Stocks Slip Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and
Is It Time To Reassess Valneva (ENXTPA:VLA) After Its Strong Recent Share Price Rally
If you are wondering whether Valneva is priced attractively right now, it helps to step back and look at what the recent share performance and valuation metrics are really telling you. The stock last closed at €5.08, with returns of 9.6% over 7 days, 23.7% over 30 days, 34.0% year to date and 39.2% over 1 year, compared with declines of 7.3% over 3 years and 52.2% over 5 years. These mixed return figures sit against a backdrop of ongoing interest in Valneva’s vaccine portfolio and...
Valneva’s Lyme disease vaccine offers beacon of hope amid 2025 sales dip
Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline candidates.